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Background: Vaccines against SARS-CoV-2 have been developed, but their availability falls far 
short of global needs. This study aimed to investigate the impact of prioritizing available doses 
on the basis of recipient antibody status, that is by exposure status, using Qatar as an example.  
Methods: Vaccination impact was assessed under different scale-up scenarios using a 
deterministic meta-population mathematical model describing SARS-CoV-2 transmission and 
disease progression in the presence of vaccination. 
Results: For a vaccine that protects against infection with an efficacy of 95%, half as many 
vaccinations were needed to avert one infection, disease outcome, or death by prioritizing 
antibody-negative individuals for vaccination. Prioritization by antibody status reduced incidence 
at a faster rate and led to faster elimination of infection and return to normalcy. Further 
prioritization by age group amplified the gains of prioritization by antibody status. Gains from 
prioritization by antibody status were largest in settings where the proportion of the population 
already infected at the commencement of vaccination was 30-60%, which is perhaps where most 
countries will be by the time vaccination programs are up and running. For a vaccine that only 
protects against disease and not infection, vaccine impact was reduced by half, whether this 
impact was measured in terms of averted infections or disease outcomes, but the relative gains 
from using antibody status to prioritize vaccination recipients were similar.    
Conclusions: Major health, societal, and economic gains can be achieved more quickly by 
prioritizing those who are antibody-negative while doses of the vaccine remain in short supply. 
Keywords: SARS-CoV-2; COVID-19; antibody; epidemiology; vaccine; mathematical model. 
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The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has been one of 
the most challenging global health emergencies in recent history [1, 2]. It is widely believed that 
vaccination offers the most effective solution to this emergency [3]. More than a hundred 
vaccines are currently under development [4], with three of them reporting efficacies as high as 
95% [5-7], but access to them remains a formidable challenge. Speed of production, logistics, 
and costs act as barriers for many countries to benefit from vaccine development. With supply 
limitations and high demand, it is foreseeable that a large proportion of the world’s population 
may not have access to these vaccines before 2022.     
Prioritizing vaccination for specific subpopulations that will benefit most from it is one potential 
approach to optimize vaccine impact while vaccine supply is being expanded. Evidence suggests 
that reinfection with SARS-CoV-2 is a rare phenomenon and that most infected persons develop 
protective immunity against reinfection that lasts for at least a few months post-primary infection 
[8-10]. Therefore, vaccination is conceivably more beneficial for those who are antibody-
negative than those whose immune systems have already confronted this infection and cleared it. 
Against this background, the objective of this study was to investigate the impact of vaccination 
with or without prioritization by antibody status (that is exposure status), using Qatar as an 
example. With the exact vaccine mechanism of action still unclear, its impact was assessed 
assuming two possible mechanisms of action, acting against both infection and disease, or acting 
only against disease. The study was possible thanks to a synergistic application of two 
innovations in public health systems: use of mathematical modeling to inform public health 
response, and use of digital healthcare systems to link diverse health information systems, create 
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and analyze databases, and use of outputs for development of mathematical models to forecast 
the epidemic trajectory, healthcare needs, and impact of interventions such as vaccination. 
METHODS 
Mathematical model 
A deterministic meta-population mathematical model was constructed to assess the impact of 
SARS-CoV-2 vaccination in Qatar by extending and adapting our previously validated and 
published models [3, 11-13]. The model description is summarized below, and further details can 
be found in the previous publications, particularly references [3, 11]. 
The model consisted of a set of coupled, nonlinear differential equations and was structured by 
age (0-9, 10-19, …, ≥80 years) and grouped by the major nationalities of the population of Qatar. 
Unvaccinated and vaccinated populations were further stratified based on infection status 
(uninfected, infected), infection stage (mild, severe, critical), and disease stage (severe, critical) 
(Figure S1). 
Susceptible populations were assumed at risk of acquiring the infection at a hazard rate that 
varies based on the infectious contact rate per day, nationality, age-specific 
exposure/susceptibility to the infection, and subpopulation mixing and age group mixing 
matrices, parametrizing mixing between individuals in different nationality and age groups. 
Infected individuals develop mild (or asymptomatic), severe, or critical infections, following a 
latency period. The proportion of infected persons developing mild, severe, or critical infections 
was age-dependent, based on relative risks that were based on the SARS-CoV-2 epidemic in 
France [14]. Severe and critical infections progress to severe and critical disease, respectively, 
prior to recovery. These are hospitalized in acute-care and ICU-care beds, respectively, based on 
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existing standards of care. Critical disease cases have an additional risk of COVID-19 mortality. 
The model was coded, fitted, and analyzed using MATLAB R2019a [15].  
Model parametrization and fitting 
Model parameterization was based on current data for SARS-CoV-2 natural history and 
epidemiology. The model was calibrated through fitting to the standardized and centralized 
databases of SARS-CoV-2 testing, infections, hospitalizations, and mortality in Qatar [16, 17], as 
well as to findings of recently-completed epidemiologic studies [16, 18-20]. Fitting to input data 
was performed using a nonlinear least square fitting technique, based on the Nelder-Mead 
simplex algorithm. 
Characteristics of the novel vaccine and its scale-up 
Since the primary end point of vaccine randomized clinical trials was efficacy against laboratory-
confirmed COVID-19 cases [6, 7, 21], and not any infection documented or undocumented, it is 
unknown whether the vaccine acted by prophylactically reducing susceptibility to the infection 
(that is SVE  efficacy, defined as the proportional reduction in susceptibility to infection among 
those vaccinated, compared to those unvaccinated [3]), or whether it simply acted by reducing 
serious symptomatic COVID-19 cases with no effect on infection (that is PVE  efficacy against 
disease progression, defined as a proportional reduction in the fraction of individuals with severe 
or critical infection among those vaccinated, but who still acquired the infection, compared to 
those unvaccinated [3]). These two mechanisms of action bracket the two extremes for the 
vaccine’s biological effect and impact, with the reduction of both infection and disease being the 
most optimistic and the reduction of only severe disease forms being the most conservative.  
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Notwithstanding this uncertainty, the impact of the vaccine was assessed assuming each of these 
mechanisms of action, 95%SVE =  and 95%PVE = , and assuming that the vaccine will offer one 
year of protection.  
Vaccine program scenarios 
Several vaccination scenarios were considered and these were informed by the availability of the 
vaccine in Qatar and the tentative schedule of its incoming shipments over the coming months. 
The first shipment of the Pfizer-BioNTech COVID-19 vaccine arrived on December 21, 2020, 
and vaccination has just been launched.  
The considered vaccination scenarios included administering the vaccine only to those who are 
antibody-negative, or irrespective of antibody status, administering a specific number of 
vaccinations or vaccinating to reach a specific coverage in a specific target population, and 
prioritizing specific age brackets as opposed to others. While the impact of vaccination in Qatar 
was the focus of this study, the generic impact of vaccination was also assessed at different 
assumed levels of infection exposure in the population at time of onset of vaccination, to reflect 
generically the diversity of the epidemic situation in different countries. 
It was assumed that the vaccine will be introduced in January 1, 2021 and will be scaled up 
within six months. Since the purpose of vaccination is to alleviate the need for restrictions that 
affect social and economic activities, it was assumed that social and physical distancing 
restrictions will be eased gradually during these six months, so that full “normalcy” will be 
attained. Normalcy was defined as a contact rate in the population that is similar to that prior to 
the pandemic, leading to a basic reproduction number 0 4R =  at the end of the six-month 
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duration for easing of restrictions. The value of 0 4R =  is justified by existing estimates of 0R  
for an epidemic in absence of interventions [22, 23].  
Measures of vaccine impact 
Direct and indirect public health benefits of vaccination were assessed. The direct impact results 
from direct effects of the vaccine ( SVE  or PVE ). The indirect impact results from the reduction 
in onward transmission of the infection, applicable only in the case of SVE . 
The total impact of the vaccine, the sum of its direct and indirect impacts, was estimated by 
comparing incidence at a given time in presence of vaccination, with that in the no-vaccination 
counter-factual scenario. Impact was also estimated by quantifying effectiveness, the number of 
vaccinations needed to avert one infection or one adverse disease outcome during a specific 
period. This metric is essentially cost-effectiveness, but with no costs included. Impact of the 
vaccine was further assessed by estimating the number of days needed to eliminate the infection 
after initiating vaccination, with infection elimination being defined as an incidence rate ≤1 
infection per 100,000 person-days. 
Uncertainty analyses  
Ranges of outcome uncertainty predicted by the model were calculated using five-hundred 
simulation runs that applied Latin Hypercube sampling [24, 25] from a multidimensional 
distribution of model parameters. At each run, input parameter values were selected from ranges 
specified by assuming ±30% uncertainty around parameter point estimates. The resulting 
distribution for each outcome predicted by the model was then used to derive the means and 
associated 95% uncertainty intervals (UIs) for vaccine effectiveness at each time point. Further 
details about this type of uncertainty analysis can be found in [11]. 
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For 500,000 vaccinations administered in the first six months of the year ( 95%SVE = ), 
vaccination of only antibody-negative persons would yield, by June 30, 2021, a reduction of 98% 
in the daily number of new infections, 83,200 averted infections, 5.9 vaccinations to avert one 
infection, and 155 days to eliminate the infection (Figure 1). Meanwhile, vaccination irrespective 
of antibody status would yield, by June 30, 2021, a reduction of 73% in the daily number of new 
infections, 40,600 averted infections, 12.0 vaccinations to avert one infection, and 228 days to 
eliminate the infection. 
For 95%SVE = , Figure 2 shows the impact of achieving vaccine coverage of 80% only among 
those who are antibody-negative, or of reaching 80% coverage in the whole population, by June 
30, 2021. As expected, the impact of the vaccine on infection is the same in both scenarios, as 
the number of people who benefited from the vaccine (only those antibody-negative) is the same 
in both scenarios. Seventy-seven days are needed to reach elimination, but elimination is reached 
with far fewer vaccinations if only those who are antibody-negative are prioritized. This is 
reflected in effectiveness, as only 8.6 vaccinations would be needed to avert one infection by 
prioritizing antibody-negative persons, but 20.6 vaccinations would be needed by vaccinating 
irrespective of antibody status. Similar results are found for gains attained by prioritizing 
according to antibody status in the case of a vaccine that only reduces disease with 95%PVE =  
(Figure S2). 
Figure 3 shows the impact of SARS-CoV-2 vaccination to reach 80% coverage among those 
antibody-negative for a vaccine that reduces both infection and disease ( 95%SVE = ) compared 
to a vaccine that reduces only disease ( 95%PVE = ). Figure 4 shows the corresponding 
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effectiveness in terms of the number of vaccinations needed to avert one severe disease case, one 
critical disease case, or one COVID-19 death. A vaccine with 95%SVE =  has a two-fold higher 
impact than a vaccine with 95%PVE = , whether this impact is measured in terms of averted 
infections or disease outcomes (Figure 3), or effectiveness in terms of the number of 
vaccinations needed to avert one disease outcome (Figure 4).   
Figure S3 shows, for 95%SVE = , the effectiveness of age-group prioritization in administering 
the vaccine only to those who are antibody-negative. Fewer vaccinations would be needed to 
avert one infection or one disease outcome by prioritizing the vaccine for those 20-49 years of 
age and older, as expected given the lower susceptibility to infection for children as opposed to 
adults. Figure S4 shows the same results, but by administering the vaccine irrespective of 
antibody status. While vaccinating those 20-49 years of age and older irrespective of antibody 
status is also more effective, the differential gains are reduced and the effectiveness has a more 
complex pattern. This complexity arises from the fact that seroprevalence varies considerably by 
age in Qatar with the lowest levels among children, followed by those >50 years of age, and is 
highest among those 20-49 years of age [16, 19, 20, 26].  
The above results show the impact of vaccination in Qatar, a country where 56.2% of the 
population is estimated, through serological surveys and mathematical modeling [11, 16, 19, 20, 
26], to have been infected by January 1, 2021, at the onset of vaccination. Meanwhile, Figure 5 
shows the impact of vaccination at different assumed levels of infection exposure in the 
population at the onset of vaccination. The figure specifically compares the number of days 
needed to eliminate the infection in a scenario in which vaccination is administered only to 
people antibody-negative at a coverage of 80%, to a scenario in which an equal number of 
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vaccinations was administered, but irrespective of antibody status. In the scenario in which only 
those antibody-negative are being vaccinated, the higher the infection exposure is at onset of 
vaccination, the less time is needed to reach elimination, as expected, as the vaccine is provided 
only to those who will directly benefit from it.  
However, the situation is more nuanced for the scenario in which individuals are vaccinated 
irrespective of antibody status. If infection exposure is very low at the onset of vaccination, less 
time would be needed to reach elimination, as the vast majority of those vaccinated are antibody-
negative and will directly benefit from the vaccine. If infection exposure is very high at onset of 
vaccination (>60%), less time would also be needed to reach elimination, as the population is 
already close to the herd immunity threshold (at 80% infection exposure for 0R  of 4), and will 
attain it quickly, even though most of those vaccinated are already antibody-positive and will not 
directly benefit from vaccination. The longest time to elimination is seen when infection 
exposure at onset of vaccination is in the intermediate range, between 30-60%, as the population 
is not close to the herd immunity threshold, but at the same time, many of those vaccinated have 
already been exposed to the infection and will not directly benefit from the vaccine. 
Figure S5 shows the results of the uncertainty analysis for vaccine effectiveness. The results 
demonstrate relatively narrow uncertainty intervals, thereby affirming the results. 
DISCUSSION 
The first finding of this study is that there are major gains by prioritizing available vaccines to 
persons who are antibody-negative, regardless of whether the vaccine reduces infection and 
disease, or just disease. With vaccine availability falling far short of global needs, such 
prioritization will reduce the incidence rate of the infection more quickly, thereby eliminating the 
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infection and returning to normalcy sooner. Vaccination would thus avert more disease cases and 
deaths and would be more cost-effective, with fewer vaccinations needed to avert one infection 
or disease outcome. As much as our results point toward substantial health, societal, and 
economic gains for vaccine prioritization by exposure status, actual implementation of such an 
approach is still contingent on the feasibility and cost of wide-scale antibody testing, as a 
component of vaccination programs in various countries, as well as equity in prioritizing the 
vaccine for some as opposed to others. 
The second finding of this study is that the gains of prioritizing vaccination by antibody status 
are largest in settings where the proportion of the population previously infected (at time of 
launch of vaccination) is between 30-60%, which is perhaps where most countries will be by the 
time vaccination programs are up and running, affirming major dividends to be reaped from this 
approach. For countries that are still at limited infection exposure, prioritization by antibody 
status will not yield such significant gains, as very few vaccinations are given to those previously 
infected, irrespective of whether prioritization is implemented.  
A third finding of this study is that the impact of the vaccine depends on whether the vaccine 
reduces infection and disease, or reduces only disease. The impact of the former was two-fold 
higher than the impact of the latter, regardless of whether this impact is measured in terms of 
averted disease cases, or in terms of the number of vaccinations needed to avert one disease 
outcome. This finding is explained by the fact that for a vaccine that reduces susceptibility to 
infection (a “ SVE ” vaccine), half of the beneficial impact is indirect, by reducing the onward 
transmission of the infection in the population, in addition to the direct impact of preventing 
infection among those vaccinated. 
All rights reserved. No reuse allowed without permission. 
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 





This study has some limitations. Model estimates are contingent on the validity and 
generalizability of input data and assumptions. Our results are based on current understanding of 
SARS-CoV-2 natural history and disease progression, but our understanding of this infection is 
still evolving. A key assumption is that those infected acquire protective immunity against 
reinfection that lasts for at least a year. While this assumption is supported by current evidence 
[8-10], studies with longer-term follow-up are still needed to assess the duration of natural 
immunity. Vaccine-induced immunity is assumed to last for one year, but the duration of this 
immunity is also unknown. Therefore, model predictions may not be valid if either duration of 
natural immunity or vaccine-induced immunity lasts less than a year, whether because of waning 
immunity or appearance of mutant virus strains that escape immunity. The model assumes that 
vaccinated persons are protected immediately once vaccinated, but vaccine protection builds up 
gradually over the course of a month following inoculation and peaks after the second does [6]. 
This may slightly reduce the gains projected here.   
In conclusion, major health, societal, and economic gains can be attained by prioritizing 
vaccination for those who are antibody-negative, as long as doses of the vaccine remain in short 
supply.     
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Figure 1: Impact of 500,000 SARS-CoV-2 vaccinations with or without prioritization by 
antibody status. Impact was assessed based upon A) the number of new infections, B) the 
cumulative number of averted infections, and C) the number of vaccinations needed to prevent 
one infection. Vaccination is introduced on January 1st, 2021 and is scaled up until June 30, 
2021, with concurrent gradual easing of social and physical distancing restrictions to reach an 
0R  of 4 by June 30, 2021. The vaccine is assumed to have an efficacy of 95% against infection: 
95%SVE = . Duration of vaccine-induced protection is one year.  
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Figure 2: Impact of SARS-CoV-2 vaccination to reach 80% coverage among only the 
antibody-negative, or to reach 80% coverage of the whole population. Impact was assessed 
based upon A) the number of new infections, B) the cumulative number of averted infections, 
and C) the number of vaccinations needed to prevent one infection. Vaccination is introduced on 
January 1st, 2021 and is scaled up until June 30, 2021, with concurrent gradual easing of social 
and physical distancing restrictions to reach an 0R  of 4 by June 30, 2021. The vaccine is 
assumed to have an efficacy of 95% against infection: 95%SVE = . Duration of vaccine-induced 
protection is one year.  
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Figure 3: Impact of SARS-CoV-2 vaccination to reach 80% coverage for a vaccine that 
reduces infection and disease ( 95%SVE = ) compared to a vaccine that reduces only disease 
( 95%PVE = ). Impact was assessed based upon A) the number of new infections per day, B) the 
number of new hospital admissions in acute-care beds per day, and C) the number of new 
hospital admissions in ICU beds per day. Only those who are antibody-negative are being 
vaccinated. Vaccination is introduced on January 1st, 2021 and is scaled up until June 30, 2021, 
with concurrent gradual easing of social and physical distancing restrictions to reach an 0R  of 4 
by June 30, 2021. Duration of vaccine-induced protection is one year.  
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Figure 4: Effectiveness of SARS-CoV-2 vaccination for a vaccine that reduces infection and 
disease ( 95%SVE = ) compared to a vaccine that reduces only disease ( 95%PVE = ). The 
number of vaccinations needed to prevent A) one severe disease case, B) one critical disease 
case, and C) one COVID-19 death. Only those antibody-negative are being vaccinated with a 
coverage of 80%. Vaccination is introduced on January 1st, 2021 and is scaled up until June 30, 
2021, with concurrent gradual easing of social and physical distancing restrictions to reach an 
0R  of 4 by June 30, 2021. Duration of vaccine-induced protection is one year. 
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Figure 5: The number of days needed to eliminate the infection after launching vaccination 
at different assumed levels of infection exposure (attack rate) in the population at time of 
vaccination onset. The number of days needed to eliminate the infection in a scenario in which 
vaccination is administered only to those who are antibody-negative at 80% coverage, is 
compared to a scenario in which an equal number of vaccinations was administered, but 
irrespective of antibody status. Vaccination is introduced on January 1st, 2021 and is scaled up 
until June 30, 2021, with concurrent gradual easing of social and physical distancing restrictions 
to reach an 0R  of 4 by June 30, 2021. The vaccine is assumed to have an efficacy of 95% against 
infection: 95%SVE = . Duration of vaccine-induced protection is one year.  
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Figure S1: Conceptual diagram illustrating the SARS-CoV-2 vaccine model. 
SVE  is defined 
as the proportional reduction in the susceptibility to infection among those vaccinated compared 
to those unvaccinated.[1] PVE  is defined as the proportional reduction in the proportion of 
individuals with severe or critical infection among those vaccinated but still acquired the 
infection compared to those unvaccinated.[1] In this figure, solid lines denote progression or 
forward movement from one population compartment to the next, while dashed lines denote 
backward movement from the present population compartment to the previous population 
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Figure S2: Impact of SARS-CoV-2 vaccination to reach 80% coverage among only the 
antibody-negative, or to reach 80% coverage of the whole population, for a vaccine that 
does not protect against infection, but protects against disease. Impact was assessed based 
upon A) the number of new hospital admissions in acute-care beds and ICU-care beds per day, 
B) the cumulative number of averted severe and critical diseases, and C) the number of 
vaccinations needed to prevent one severe or critical disease case. Vaccination is introduced on 
January 1st, 2021 and is scaled up until June 30, 2021, with concurrent gradual easing of social 
and physical distancing restrictions to reach an 0R  of 4 by June 30, 2021. The vaccine is 
assumed to have an efficacy of 95% against only disease: 95%PVE = . Duration of vaccine-
induced protection is one year. 
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Figure S3: Effectiveness of age-group prioritization in vaccinating only antibody-negative 
persons. The number of vaccinations needed to prevent A) one infection, B) one severe disease 
case, C) one critical disease case, and D) one COVID-19 death. Vaccination is introduced on 
January 1st, 2021 and is scaled up until June 30, 2021, with concurrent gradual easing of social 
and physical distancing restrictions to reach an 0R  of 4 by June 30, 2021. The vaccine is 
assumed to have an efficacy of 95% against infection: 95%SVE = . Duration of vaccine-induced 
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Figure S4: Effectiveness of age-group prioritization in vaccinating regardless of antibody 
status. The number of vaccinations needed to avert A) one infection, B) one severe disease case, 
C) one critical disease case, and D) one COVID-19 death. Vaccination is introduced on January 
1st, 2021 and is scaled up until June 30, 2021, with concurrent gradual easing of social and 
physical distancing restrictions to reach an 0R  of 4 by June 30, 2021. The vaccine is assumed to 
have an efficacy of 95% against infection: 95%SVE = . Duration of vaccine-induced protection 
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Figure S5: Uncertainty analysis. The mean and 95% uncertainty interval (UI) for the 
effectiveness of SARS-CoV-2 vaccination with or with no prioritization by antibody status for a 
vaccine that reduces infection and disease ( 95%SVE = ) compared to a vaccine that reduces only 
disease ( 95%PVE = ). The number of vaccinations needed to avert A) one infection A) one 
severe disease case, B) one critical disease case, and C) one COVID-19 death. Vaccination is 
introduced on January 1st, 2021 and is scaled up until June 30, 2021, with concurrent gradual 
easing of social and physical distancing restrictions to reach an 0R  of 4 by June 30, 2021. 
Duration of vaccine-induced protection is one year. 
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